Cart
sales@molnova.com
JW55
CAS No. 664993-53-7
JW55( Tankyrase 1/2 Inhibitor IV )
Catalog No. M15535 CAS No. 664993-53-7
JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 73 | In Stock |
|
| 25MG | 143 | In Stock |
|
| 50MG | 246 | In Stock |
|
| 100MG | 408 | In Stock |
|
| 500MG | 945 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJW55
-
NoteResearch use only, not for human use.
-
Brief DescriptionJW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively.
-
DescriptionJW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively.
-
In Vitro——
-
In Vivo——
-
SynonymsTankyrase 1/2 Inhibitor IV
-
PathwayMetabolic Enzyme/Protease
-
TargetPPAR
-
RecptorTNKS1| TNKS2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number664993-53-7
-
Formula Weight434.48
-
Molecular FormulaC25H26N2O5
-
Purity>98% (HPLC)
-
SolubilityDMSO, Ethanol: 100 mM
-
SMILESO=C(C1=CC=CO1)NC2=CC=C(C(NCC3(C4=CC=C(OC)C=C4)CCOCC3)=O)C=C2
-
Chemical NameN-(4-(((4-(4-methoxyphenyl)tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)phenyl)furan-2-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Waaler J, et al. Y Res. 2012 Jun 1;72(11):2822-32.
molnova catalog
related products
-
Hydroxyfasudil Hydro...
Hydroxyfasudil hydrochloride is a ROCK1/2 inhibitor (IC50s: 0.73/0.72 μM).
-
Rosiglitazone
A potent and selective PPARγ agonist that binds to the PPARγ ligand-binding domain with a Kd of 40 nM.
-
SR 16832
SR 16832 is a dual-site PPARγ inhibitor. It also inhibits the binding of endogenous ligands and transcriptional activity of PPARγ, more effectively than the orthosteric covalent antagonist GW 9662 and T 0070907.
